GRM3 Antibody, HRP conjugated

1. Research suggests that mGlu3Delta4 may negatively regulate mGlu3, thereby influencing the role of GRM3/mGlu3 in schizophrenia and its potential as a therapeutic target. PMID: 28655286
2. Our findings support the association identified in genome-wide association studies (GWAS) between GRM3 genetic variations and schizophrenia risk. Moreover, these findings suggest that alleles associated with this risk may exhibit population-specific variations. PMID: 28786982
3. Studies have shown that GRM3 expression is significantly elevated in human colonic adenocarcinomas and colon cancer cell lines. This upregulation occurs at the post-transcriptional level, where miR-487b directly targets GRM3 to suppress its translation. Additionally, the observation that TGFbeta enhances GRM3 protein stability provides novel insights into the post-transcriptional regulation of GRM3 in colon cancer. PMID: 28114282
4. Low GRM3 expression has been associated with multiple myeloma and B-cell leukemia. PMID: 27431857
5. A significant association was observed between rs12704290 in the GRM3 gene and schizophrenia (SCZ). A three-SNP linkage disequilibrium spanning the GRM3Delta4 splice site was also significantly associated with SCZ. Furthermore, an interaction between the linkage disequilibrium block and cognitive function was identified in SCZ patients. PMID: 26187343
6. Results demonstrate that individuals carrying the GRM3 rs274622 C allele with schizophrenia exhibited significantly smaller prefrontal activation compared to patients with the TT genotype. PMID: 25914064
7. Grm3 expression was found to be decreased in B cells from patients with autoimmune diseases such as activated systemic lupus erythematosus and multiple sclerosis. PMID: 26071318
8. Pharmacogenetic relationships have been identified in patients with schizophrenia between GRM3 variants and the response to antipsychotic medications. PMID: 25096017
9. Polymorphisms in PI4KA and GRM3 have the potential to jointly modulate antipsychotic response. PMID: 25209194
10. The mGluR3 receptor promoted the proliferation of human embryonic cortical neural progenitor cells and increased cyclin D1 expression by activating ERK1/2 and JNK2 signaling pathways. PMID: 25198581
11. Research suggests an association of the GRM3 rs6465084 polymorphism with changes in pursuit maintenance following antipsychotic treatment. PMID: 24682224
12. This study provided evidence for an association between GRM3 genotype and schizophrenia, suggesting a role for glutamate neurotransmission in the development and maintenance of myelinated fibers. PMID: 24680030
13. Results provide the first evidence that polymorphisms in the GRM3 gene are associated with the prevalence of alcohol dependence in humans. PMID: 24585043
14. This report describes a novel neuroprotective function of mGlu3 receptors related to their ability to promote the non-amyloidogenic pathway of amyloid precursor protein (APP) cleavage in astrocytes, thereby enhancing the production of sAPPalpha. PMID: 24291464
15. Data indicate that metabotropic glutamate receptor subtype 3 (mGluR3) polymorphisms do not contribute to genetic susceptibility to schizophrenia and depression, but they confer an increased risk of heroin dependence (HD) in a Chinese population. PMID: 24498053
16. The transcript of mGlu3 receptors should be measured in tumor specimens to accurately predict patient survival in response to temozolomide treatment. PMID: 23175182
17. A Kozak sequence variant associated with bipolar disorder PMID: 23575746
18. Glutamate system dysfunction may play a role in the prefrontal functional abnormalities observed in alcoholism. Certain GRM3 SNP genotypes may further decrease NAA/Cr levels and executive function in addition to the effects of alcohol. PMID: 22909248
19. Polymorphisms in the GRM3 gene may be associated with refractory global psychosis symptoms, but not negative symptoms, in individuals with schizophrenia. PMID: 21344500
20. Analysis suggests that mGluR3 is the primary mGlu receptor expressed by adult cortical astrocytes, while the expression of other mGluRs was low or absent. PMID: 23307741
21. These results suggest that variations in GRM3 genotype influence the auditory cortical response to phoneme change in humans. PMID: 22022368
22. Melanoma cells expressing mutant GRM3 exhibited reduced cell growth and cellular migration following short hairpin RNA-mediated knockdown of GRM3 or treatment with a selective MEK inhibitor, AZD-6244, currently being used in phase 2 clinical trials. PMID: 21946352
23. This study suggests a gene-environment (G x E) interaction between GRM3 gene variants and severe obstetric complications on hippocampus volume, independent of a diagnosis of schizophrenia. PMID: 20638435
24. Findings strongly suggest that genetic variation (rs17676277 and three haplotypes) in the metabotropic glutamate receptor 3 is related to cognitive set-shifting in healthy individuals, independent of working memory. PMID: 20132315
25. An association was found between one marker (rs6465084) in the glutamate receptor gene GRM3 and Japanese patients with major depressive disorder. PMID: 19386277
26. Results define a microenvironment within the binding pocket that includes several positively charged amino acids that recognize the negatively charged phosphonate group of l-AP4 or the endogenous compound l-serine-O-phosphate. PMID: 11744707
27. Genetic variation in the metabotropic glutamate receptor 3 gene may contribute to genetic predisposition to schizophrenia and/or bipolar affective disorder. PMID: 11840505
28. At least one susceptibility locus for schizophrenia is situated within or very close to the GRM3 region in Japanese patients. PMID: 12782962
29. mGluR3 and mGluR5 can critically and differentially modulate the expression of glutamate transporters and may represent interesting pharmacological targets to regulate extracellular glutamate levels in pathological conditions. PMID: 12786977
30. Glial progenitor cells present in the adult human central nervous system (CNS) express mGluR3 and mGluR5a. PMID: 15158450
31. This research defines the essential requirements for ligand binding to the extracellular domain of mGluR3 and highlights parameters important for optimizing receptor expression in mammalian cells. PMID: 15178451
32. The reduction of mGluR3 immunopositive product in the stratum lacunosum moleculare of hippocampal CA1 is a consequence of neuronal loss in either the entorhinal cortex or CA1 area of the hippocampus. PMID: 15246118
33. Data suggest a specific molecular pathway by which metabotropic glutamate receptor GRM3 alters glutamate neurotransmission, prefrontal and hippocampal physiology and cognition, thereby increasing the risk for schizophrenia. PMID: 15310849
34. MGluR3 modulates the release of IL-6 in the presence of IL-1beta, supporting the role of mGluR3 in regulating the inflammatory and immune response associated with gliosis. PMID: 15652990
35. GRM3 polymorphism may be associated with improvement in negative symptoms in individuals with schizophrenia treated with olanzapine. PMID: 15913960
36. The existence of the GRM3Delta4 isoform is significant in light of the reported association of non-coding single nucleotide polymorphisms (SNPs) in GRM3 with schizophrenia. PMID: 16417579
37. SNPs in RGS4, G72, GRM3, and DISC1 showed evidence for significant statistical epistasis with COMT. PMID: 17006672
38. mGlu3 receptor levels are altered in schizophrenia. PMID: 17531207
39. This research extends putative brain dopaminergic and glutamatergic relationships indexed by catechol-O-methyltransferase and GRM3 to a systems-level interaction in human cortical circuits implicated in working memory dysfunction, such as in schizophrenia. PMID: 17636131
40. The current study genotyped rs274622 in the promoter region of GRM3. None of the polymorphisms analyzed were associated with schizophrenia. PMID: 17948896
41. Single nucleotide polymorphisms were not associated with schizophrenia. PMID: 18075480
42. The study of DNA sequence variants in the GRM3 gene did not provide further support for genetic association with schizophrenia or for correlation with cognitive deficits. PMID: 18197082
43. An exon 3 single nucleotide polymorphism (SNP) in GRM3 predicts increased splicing of the fourth exon and may contribute to the risk for schizophrenia by modulating GRM3 splicing. PMID: 18256595
44. The results of this study indicate that the rs6465084 functional polymorphism in GRM3 does not contribute to genetic susceptibility to schizophrenia. PMID: 18412850
45. These data implicate mGluR3 in the etiological, pathophysiological, and pharmacotherapeutic aspects of schizophrenia – REVIEW PMID: 18541626
46. Our results provide further evidence for the potential importance of the glutamate receptor GRM3 in schizophrenia and indicate that the novel antipsychotic LY2140023 may actually be targeting a pathogenic pathway of schizophrenia. PMID: 18614340
47. These data suggest that Glutamate receptor metabotropic 3 glutamate metabotropic receptor is disrupted in the anterior hippocampus (AH) in schizophrenia and localize the defect to the CA1 and CA3 regions. PMID: 19403271
48. The current Scandinavian results do not verify previous associations between the analyzed DTNBP1, NRG1, DAO, DAOA, and GRM3 gene polymorphisms and schizophrenia. PMID: 19439994

Show More

Hide All

HGNC: 4595

OMIM: 601115

KEGG: hsa:2913

STRING: 9606.ENSP00000355316

UniGene: Hs.590575